UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                        Commission File Number: 000-50956

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

(Check One):  [_] Form 10-K and Form 10-KSB    [_] Form 20-F     [_] Form 11-K

              [X] Form 10-Q and Form 10-QSB    [_] Form N-SAR

  For Period Ended: April 30, 2006

      [_] Transition Report on Form 10-K     [_] Transition Report on Form 10-Q
      [_] Transition Report on Form 20-F     [_] Transition Report on Form N-SAR
      [_] Transition Report on Form 11-K

      For the Transition Period Ended :________________________

      Read attached instruction sheet before preparing form. Please print or
type.

      Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

      If the notification related to a portion of the filing checked above,
identify the item(s) to which the notification relates:

                                     PART I
                             REGISTRANT INFORMATION


Full name of registrant: Pharma-Bio Serv, Inc.

      Former name if applicable: _________________________________________
Address of principal executive office: 373 Mendez Vigo, Suite 110, Dorado,
Puerto Rico 00646


                                     PART II
                             RULE 12b-25 (b) and (c)

      If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

[X]         (a)   The reasons described in reasonable detail in Part III of
                  this form could not be eliminated without unreasonable effort
                  or expense.

[X]         (b)   The subject annual report, semi-annual report, transition
                  report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion
                  thereof will be filed on or before the fifteenth calendar day
                  following the prescribed due date; or the subject quarterly
                  report or transition report on Form 10-Q or portion thereof
                  will be filed on or before the fifth calendar day following
                  the

            (c)   The accountant's statement or other exhibit required by Rule
                  12b-25(c)has been attached if applicable.



                                    PART III
                                    NARRATIVE

      State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period.

      The Company's Quarterly Report on Form 10-QSB for the quarterly period
ended April 30, 2006 cannot be filed within the prescribed time period because
the Company requires additional time for compilation and review to insure
adequate disclosure of certain information required to be included in the Form
10-QSB. The Company's Quarterly Report on Form 10-QSB will be filed on or before
the 5th calendar day following the prescribed due date.

                                     PART IV
                                OTHER INFORMATION

      (1)   Name and telephone number of person to contact in regard to this
            notification: Manuel O. Morera, Chief Finanial Officer,
            787-278-2709.

      (2)   Have all other periodic reports required under Section 13 or 15(d)
            of the Securities Exchange Act of 1934 or Section 30 of the
            Investment Company Act of 1940 during the preceding 12 months or for
            such shorter period that the registrant was required to file such
            report(s) been filed? If the answer is no, identify report(s)
            [X] Yes [ ] No
      (3)   Is it anticipated that any significant change in results of
            operations from the corresponding period for the last fiscal year
            will be reflected by the earnings statements to be included in the
            subject report or portion thereof? [ ] Yes [X] No

            If so, attach an explanation of the anticipated change, both
            narratively and quantitatively, and, if appropriate, state the
            reason why a reasonable estimate of the results cannot be made.

                              Pharma-Bio Serv, Inc.
                  (Name of Registrant as specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date: June 14, 2006                              By: /s/ Manuel O. Morera
                                                     ---------------------------
                                                         Manuel O. Morera
                                                         Chief Financial Officer

                                       2